

CONTENTS

Preface

page xvii

1 The clinical necessity of biomaterials in the twenty-first century	1
1.1 Health care products in medical practice	1
1.1.1 The ubiquitous low back pain	2
1.1.2 Sporting injuries and arthritis	3
1.1.3 The end of the road for cataracts	6
1.1.4 The challenge of Parkinson's disease	6
1.1.5 The cath lab and beyond	8
1.1.6 Pulses and shocks in the heart	10
1.1.7 Care of the newborn	11
1.1.8 Diagnosing and treating breast cancer	12
1.1.9 The challenge of diabetes	13
1.1.10 The messy business of incontinence	15
1.2 The ubiquity of materials in clinical medicine	16
1.3 The biomaterials concept	17
1.4 The evolution of biomaterials science and the changing concepts	19
1.4.1 Early implantable devices	19
1.4.2 The emergence of regenerative medicine	20
1.4.3 Nanotechnology, diagnostics and drug delivery	21
1.4.4 The current definition of a biomaterial	22
1.5 The classification of biomaterials applications	22
1.6 The components of biomaterials science	22
Summary and learning objectives	26
Questions	27
Recommended reading	28
2 Essential materials science	29
2.1 Introduction	29
2.2 The basic materials model	30
2.3 Atoms, molecules, interatomic and intermolecular bonds	38
2.3.1 Atoms and the nature of elements	38
2.3.2 Interactions between atoms	40
2.3.3 Interactions between molecules	43
2.4 The organization of atoms and molecules: states of matter, crystalline and amorphous materials	44
2.4.1 The states of matter	44
2.4.2 Crystallinity	44
2.4.3 Macro-, micro- and nano structures	51

2.5	Surface properties of materials	54
2.5.1	Surface energy: the hydrophilic/hydrophobic balance	54
2.5.2	Surface chemistry	56
2.5.3	Surface topography	60
2.5.4	Techniques for surface modification	61
2.5.5	Special considerations at the nanoscale	65
2.6	Practical materials	65
2.6.1	Metals and alloys	65
2.6.2	Synthetic structural polymers, plastics, elastomers and textiles	68
2.6.3	Biopolymers	72
2.6.4	Ceramics, glasses and glass-ceramics	72
2.6.5	Bioceramics	73
2.6.6	Composites	73
2.6.7	Natural composites	75
2.7	Physical properties of materials	76
2.7.1	Thermal properties	76
2.7.2	Electrical properties	77
2.7.3	Electronic and optoelectronic properties	78
2.7.4	Magnetic properties	81
2.7.5	Ultrasound	82
2.8	Mechanical properties of materials	83
2.8.1	Forces and stress: deformation and strain	83
2.8.2	Elasticity and plasticity	85
2.8.3	Fracture, ductility and toughness	88
2.8.4	Time-dependent deformation: fatigue, creep and viscoelasticity	93
2.8.5	Hardness	96
2.8.6	Friction and wear	96
2.9	Corrosion and degradation mechanisms	99
2.9.1	Metallic corrosion	101
2.9.2	Polymer degradation	106
2.9.3	Ceramic degradation	110
2.9.4	Performance of composites	112
2.10	Synthesis, fabrication and manufacturing considerations	112
2.10.1	Metallurgical processes	112
2.10.2	Polymer processing	113
2.10.3	Ceramic processing	114
2.10.4	Composites	115
2.10.5	Sterilization	115
2.11	Environmental responsiveness	116
2.11.1	Thermally responsive polymers	116
2.11.2	pH responsive materials	118
2.11.3	Shape memory materials	118
2.12	Special considerations	119
2.12.1	Nanoparticles as biomaterials	119

2.12.2	Injectable materials	122
2.12.3	Self-assembly	123
2.12.4	Biomimetic materials	123
	Summary and learning objectives	124
	Questions	125
	Recommended reading	126
3	Biocompatibility pathways	129
3.1	Introduction	129
3.2	The fundamental biocompatibility paradigm	135
3.2.1	Some general principles	138
3.2.2	The components of biocompatibility	139
3.2.3	A systems approach	140
3.3	Biocompatibility scenarios	141
3.3.1	Introduction to biocompatibility mechanisms and pathways	141
3.3.2	Scenario A: Mechanisms of biocompatibility that do not rely on direct chemical interactions between the biomaterial and the host	143
3.3.3	Scenario B: Mechanisms of biocompatibility involving chemical reactions between macroscale biomaterials and their soluble derivatives with the host	161
3.3.4	Scenario C: Mechanisms of biocompatibility involving microscale biomaterials and microparticles	183
3.3.5	Scenario D: Mechanisms of biocompatibility involving nanoscale biomaterials	193
3.3.6	Scenario E: Mechanisms of biocompatibility involving delivery of pharmaceutical agents from macroscale biomaterials to host	200
3.4	Systemic or remote site biocompatibility	208
3.4.1	Reproductive toxicology	208
3.4.2	Carcinogenicity	210
3.4.3	Autoimmunity	211
3.5	The unified framework of biocompatibility	212
3.5.1	The generic biocompatibility pathway	212
3.5.2	Target cells, defensive cells and interfering cells	212
3.5.3	Cellular mechanisms in biocompatibility pathways	215
3.6	Specific clinical examples of biocompatibility phenomena	216
3.6.1	Osteoinduction, osteoconduction and osseointegration	216
3.6.2	Heart valves	218
3.6.3	Blood vessels	220
3.6.4	Nerve repair	222
3.7	Influences of bacteria, fungi, viruses, prions and endotoxins	223
3.7.1	Biofilms	224
3.7.2	Material variables and bacterial adhesion	224
3.7.3	Clinical aspects	225
3.7.4	Avoidance and treatment of bacterial infection	226

3.7.5	Fungi	226
3.7.6	Viruses	227
3.7.7	Prions	227
3.7.8	Endotoxins	227
3.8	Clinical and patient variables	227
3.8.1	Clinical technique	228
3.8.2	Patient variables	228
3.8.3	General comments	228
	Summary and learning objectives	229
	Questions	231
	Recommended reading	232

4	Implantable medical devices and artificial organs	236
4.1	Orthopedics	236
4.1.1	Joint replacement	238
4.1.2	Ligaments and tendons	254
4.1.3	The spinal column	255
4.1.4	Bone defects	259
4.1.5	Bone fracture	260
4.1.6	Cartilage defects	262
4.2	The cardiovascular system	263
4.2.1	Arteries and veins	263
4.2.2	Valves	271
4.2.3	Congenital heart defects	279
4.2.4	Myocardial infarction	280
4.2.5	Arrhythmias	280
4.2.6	Heart failure	283
4.3	The major organs: liver, kidney, lungs, pancreas	284
4.3.1	The kidney: hemodialysis	285
4.3.2	The lungs: extracorporeal membrane oxygenation	286
4.3.3	The liver	286
4.3.4	The pancreas: insulin pumps	287
4.4	Eyes and ears	287
4.4.1	Contact lenses	287
4.4.2	Intraocular lenses	288
4.4.3	Glaucoma	289
4.4.4	Retina and artificial vision	290
4.4.5	External ear	291
4.4.6	Middle ear	291
4.4.7	Cochlear	292
4.5	Central nervous system	293
4.5.1	Hydrocephalus shunts	294
4.5.2	Deep brain stimulator	294
4.5.3	Neural recording electrodes	295

4.6	Genito-urinary system	296
4.6.1	The bladder	296
4.6.2	The overactive bladder in children	296
4.6.3	Ureteral patency	296
4.6.4	Urinary incontinence	297
4.6.5	Pelvic organ prolapse	298
4.6.6	Penile reconstruction	299
4.6.7	Testicular implants	299
4.7	Gastrointestinal system	299
4.7.1	Gastric bands	299
4.7.2	Anti-reflux devices	300
4.7.3	Gastrointestinal stents	300
4.8	Reproductive system	300
4.8.1	Intravaginal devices	301
4.8.2	Intrauterine devices	301
4.9	Dentistry, maxillofacial and craniofacial tissues	301
4.9.1	Oral cancer	301
4.9.2	Dental implants	302
4.9.3	Craniofacial reconstruction	302
4.10	General soft tissue repair, replacement and augmentation	303
4.10.1	Hernia	303
4.10.2	Breast reconstruction	304
4.11	Commentary on implantable devices	306
	Summary and learning objectives	306
	Questions	308
	Recommended reading	309

5	Regenerative medicine and tissue engineering	313
5.1	Introduction to regenerative medicine	313
5.2	The basic tissue engineering paradigms	315
5.3	Cells for tissue engineering	319
5.3.1	Cell sources	319
5.3.2	Principles of cell manipulation	331
5.3.3	Cell patterning	332
5.3.4	Cell sheet engineering	332
5.4	Biomolecules and nutrients for tissue engineering	334
5.4.1	Culture media and oxygenation	335
5.4.2	Growth factors	338
5.4.3	Gene transfer in tissue engineering	339
5.5	Biomaterials for regenerative medicine and tissue engineering processes	340
5.5.1	Background	340
5.5.2	The concept of tissue engineering templates	341
5.5.3	The objectives of tissue engineering templates	342

5.5.4	Classification of tissue engineering templates	343
5.5.5	Specifications for template materials	344
5.5.6	Specific types of template material	352
5.5.7	Fluid mechanics and templates	360
5.5.8	Fabrication routes for solid templates	362
5.5.9	Bioprinting and organ printing	366
5.6	Tissue engineering and clinical reality	367
5.6.1	Bone tissue engineering	367
5.6.2	Cartilage tissue engineering	369
5.6.3	Skin tissue engineering	371
5.6.4	Skeletal muscle tissue engineering	373
5.6.5	Vascular tissue engineering	376
5.6.6	Cardiac tissue engineering: the myocardium	378
5.6.7	Cardiac tissue engineering: heart valves	382
5.6.8	Nerve tissue engineering	383
5.6.9	Urological tissue engineering	384
5.6.10	Airway tissue engineering	386
5.7	Tissue engineering of constructs for drug testing and tumor models	388
	Summary and learning objectives	389
	Questions	390
	Recommended reading	391
6	Drug and gene delivery	393
6.1	Introduction to active molecule delivery	393
6.1.1	Rationale for drug delivery technologies	394
6.1.2	Oral drug delivery	399
6.2	Non-oral delivery of conventional drugs	400
6.2.1	Transdermal delivery	400
6.2.2	Implantable electromechanical systems	404
6.3	Drug release from solid polymers in monolithic devices	404
6.3.1	Mechanisms of release	406
6.3.2	Solid polymers for drug release	408
6.4	Drug release from microparticulate and nanoparticulate systems	409
6.4.1	Microparticles and drug delivery	410
6.4.2	Nanoparticles and drug delivery	411
6.5	Polymer therapeutics	415
6.5.1	Polymeric drugs	416
6.5.2	Polymer-active agent conjugates	417
6.5.3	Polymer architecture	420
6.6	Cancer: chemotherapy and immunotherapy	421
6.6.1	Localized delivery of chemotherapeutic agents	421
6.6.2	Targeting chemotherapeutic agents to tumors	421
6.7	Gene therapy and transfer	426
6.7.1	The concept of gene therapy	426

6.7.2	Viral vectors	426
6.7.3	Non-viral vectors	428
6.8	Vaccines	434
6.9	Antimicrobial agents	435
6.9.1	Antibacterial agents and antibiotics	435
6.10	Combinations of systems	439
6.10.1	Theranostic agents	441
6.10.2	Drug-device combinations	443
	Summary and learning objectives	443
	Questions	444
	Recommended reading	445
7	Imaging and diagnostic systems	448
7.1	Introduction	448
7.1.1	Anatomical and functional imaging	448
7.1.2	Principles of molecular imaging	450
7.2	Magnetic resonance imaging	451
7.2.1	T1 agents	453
7.2.2	T2 agents	453
7.2.3	CEST and PARACEST	454
7.2.4	¹⁹ F agents	455
7.3	CT imaging	455
7.4	PET and SPECT imaging	456
7.5	Ultrasound imaging	458
7.6	Optical imaging	459
7.6.1	Upconversion nanoparticles	460
7.6.2	Quantum dots	463
7.7	Multi-modal imaging	466
7.8	Theranostics	466
7.9	Biosensors	467
7.9.1	The principles of sensing chemical and biological agents in tissues	467
7.9.2	Enzyme-based biosensors	467
7.9.3	Immunosensors	468
7.10	General comments on nanoparticle toxicity in imaging systems	469
7.10.1	Clinically observed effects	469
7.10.2	Nanoparticle toxicity and biodistribution	470
	Summary and learning objectives	470
	Questions	472
	Recommended reading	473
8	Contemporary and future biomaterials	475
8.1	The classification of biomaterials	476
8.2	Class 1 The metallic systems	477
8.2.1	Class 1.1 Titanium and titanium alloys	477

8.2.2	Class 1.2 Iron and steels	481
8.2.3	Class 1.3 Cobalt-based alloys	484
8.2.4	Class 1.4 Nickel-based alloys	486
8.2.5	Class 1.5 Tantalum and zirconium alloys	487
8.2.6	Class 1.6 Silver	488
8.2.7	Class 1.7 Platinum group metals and alloys	489
8.2.8	Class 1.8 Gold	492
8.2.9	Class 1.9 Magnesium and its alloys	493
8.3	Class 2 The ceramics systems	495
8.3.1	Class 2.1 Oxides	497
8.3.2	Class 2.2 Phosphates	505
8.3.3	Class 2.3 Sulfates	507
8.3.4	Class 2.4 Silicates and silica-based glasses	507
8.3.5	Class 2.5 Nitrides	508
8.3.6	Class 2.6 Carbides	508
8.3.7	Class 2.7 Titanates	509
8.3.8	Class 2.8 Optically active ceramic/metallic nanoparticles	510
8.4	Class 3 The polymeric systems	511
8.4.1	Class 3.1 Thermoplastic polymers	515
8.4.2	Class 3.2 Thermosetting resins	525
8.4.3	Class 3.3 Synthetic polymeric sols and gels	525
8.4.4	Class 3.4 Proteins and peptides	529
8.4.5	Class 3.5 Polysaccharides	537
8.4.6	Class 3.6 Lipids	542
8.4.7	Class 3.7 Biodegradable structural polymers	544
8.4.8	Class 3.8 Water-soluble polymers	554
8.4.9	Class 3.9 Polymers with ionizable or ionic groups	557
8.4.10	Class 3.10 Elastomers	559
8.4.11	Class 3.11 Fibers, fabrics and textiles	565
8.4.11	Class 3.12 Environmentally responsive polymers	568
8.5	Class 4 Carbon materials	568
8.5.1	Class 4.1 <i>Diamond and diamond-like materials</i>	569
8.5.2	Class 4.2 Graphitic materials	572
8.5.3	Class 4.3 Glassy or vitreous carbon	573
8.5.4	Class 4.4 Hexagonally bonded carbon nanostructures	573
8.6	Class 5 Composite materials	575
8.6.1	Class 5.1 Fiber reinforced thermoplastic polymers	576
8.6.2	Class 5.2 Fiber reinforced resins	576
8.6.3	Class 5.3 Ceramic microparticle reinforced biostable polymers	576
8.6.4	Class 5.4 Ceramic microparticle reinforced biodegradable polymers	577
8.6.5	Class 5.5 Nanocomposites	577
8.7	Class 6 Engineered biological materials	577
8.7.1	General comments on tissue processing	578
8.7.2	Class 6.1 Autologous tissues	580

8.7.3	Class 6.2 Allogeneic tissues	580
8.7.4	Class 6.3 Xenogeneic tissues	582
	Summary and learning objectives	583
	Questions	584
	Recommended reading	585
9	Infrastructure of the biomaterials industry	590
9.1	Introduction	590
9.2	Principles of medical technology regulation	591
9.2.1	Risk assessment and risk management	592
9.2.2	Regulation in the USA	594
9.2.3	Regulation in Europe	598
9.2.4	Regulation in the Asia-Pacific region	599
9.3	Biomaterials and medical device standards and guidelines	603
9.3.1	Standards for the pre-clinical testing of biomaterials	604
9.4	Clinical trials and post-market surveillance	606
9.4.1	Clinical trials of health care products	606
9.4.2	Post-market surveillance	607
9.4.3	Implant registries	608
9.5	Product liability litigation in medical technology	609
9.5.1	The Dalkon Shield	609
9.5.2	Proplast and the temporomandibular joint	610
9.5.3	The Bjork–Shiley heart valve	611
9.5.4	The silicone breast implant story	612
9.5.5	Silzone heart valves	613
9.5.6	General observations	614
9.6	Health economics and social policy	614
9.6.1	Global inequalities in health and health care	615
9.6.2	Medical technology as a driver of economy	616
9.6.3	Medical technologies, cost-effectiveness and quality of life	616
9.7	Intellectual property	617
9.8	Ethical issues	618
9.8.1	Research data and publishing	619
9.8.2	Intellectual property	619
9.8.3	Regulatory submissions	620
9.8.4	Organ transplantation and organ assist	621
9.8.5	Animal tissues	622
9.8.6	Stem cells and human-derived products	623
9.8.7	Commercialization of the human body	623
9.8.8	Clinical trials	624
9.8.9	Marketing	625
9.8.10	Product recalls	625
9.8.11	Off-label use	625
9.8.12	Re-use of single-use items	626

9.8.13	Developing countries	627
9.8.14	The overall relationships between doctors/medical associations and industry	627
	Summary and learning objectives	628
	Questions	629
	Recommended reading	630
	<i>Index</i>	631

The colour plates are situated between pp. 396 and 397